Prediction of disease activity and treatment failure in relapsing-remitting MS patients initiating daily oral DMTs.
Agustin PappollaCristina AugerAugusto Sao-AvilesCarmen TurMarta Rodriguez-BarrancoÁlvaro Cobo-CalvoNeus Mongay-OchoaBreogan Rodriguez AcevedoAnna ZabalzaLuciana MidagliaPere Carbonell-MirabentRene CarvajalJoaquín Castilló-JustribóNathane BragaLuca BolloÁngela Vidal-JordanaGeorgina ArrambideCarlos NosAnnalaura SalernoIngrid GalánManuel ComabellaJaume Sastre-GarrigaMar TintoreÀlex RoviraXavier MontalbanJordi RíoPublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2024)
Scoring systems present different predictive abilities for disease activity parameters at 36 months in MS patients initiating daily oral therapies, warranting further adjustments (i.e. introduction of fluid biomarkers) to depict disease activity status fully.
Keyphrases
- disease activity
- rheumatoid arthritis
- systemic lupus erythematosus
- rheumatoid arthritis patients
- ankylosing spondylitis
- multiple sclerosis
- end stage renal disease
- juvenile idiopathic arthritis
- chronic kidney disease
- newly diagnosed
- ejection fraction
- mass spectrometry
- ms ms
- patient reported outcomes
- smoking cessation